Article

Early efficacy results favorable for systemic anti-VEGF treatment for CNV

Systemic bevacizumab (Avastin) therapy in patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration has been associated with functional and anatomic improvements, according to early results from an open-label, uncontrolled clinical study undertaken at Bascom Palmer Eye Institute, Miami, FL.

May 4

- Fort Lauderdale, FL - Systemic bevacizumab (Avastin) therapy in patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration has been associated with functional and anatomic improvements, according to early results from an open-label, uncontrolled clinical study undertaken at Bascom Palmer Eye Institute, Miami, FL.

"While this agent appears to have promising efficacy, it has higher systemic risks than any other drugs we are currently using, and we need to determine with further study if its benefits exceed the risks," stated Philip J. Rosenfeld, MD, PhD, who spoke on behalf of the Systemic bevacizumab (Avastin) therapy for Neovascular Age-related macular degeneration (SANA) study group.

Bevacizumab is an anti-VEGF humanized monoclonal antibody that binds to all biologically active isoforms of VEGF. It is commercially available and approved by the FDA for treatment of metastatic colorectal cancer in conjunction with chemotherapy.

One eye of patients enrolled in SANA was identified as the study eye. It was required to have recent disease progression and the patient must have been either not a candidate for verteporfin (Visudyne) photodynamic therapy or refused that treatment. Fifteen of 18 patients had evidence of CNV in their fellow eye.

Six months of follow-up was available for an initial cohort of nine patients and a second cohort of nine patients had been followed for 3 months. Treatment was with the oncology recommended dose of 5 mg/kg, but patients received only two or three doses given at 2-week intervals. Additional treatment was received by three of the first nine patients in the first cohort who had worsening acuity and/or increased retinal thickness.

Results of efficacy analyses performed after 3 to 6 months showed improvements in both study and fellow eyes with CNV with regard to visual acuity, fluorescein and ICG angiography, and OCT-measured central retinal thickness.

The treatment has been well-tolerated so far, but onset or worsening of hypertension occurred in 10 of 18 patients.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.